Aktie A2JAAW APELLIS PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Apellis Pharmaceuticals, Inc.

Aktien

A2JAAW

US03753U1060

APLS

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 28.05.2024 		% 5 Tage % 1. Jan.
40,56 USD -0,12 % Intraday Chart für Apellis Pharmaceuticals, Inc. -6,15 % -32,24 %
24.05. Apellis Pharmaceuticals und Sobi: Pegcetacoplan reduziert Nierenerkrankungen nach Transplantation MT
24.05. Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals, Inc. gibt positive Ein-Jahres-Ergebnisse der Phase-2-Studie zu Pegcetacoplan bei C3G- und IC-MPGN-Rezidiven nach Transplantationen bekannt, die als Late-Breaker auf dem ERA-Kongress präsentiert wurden CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing
Apellis Pharmaceuticals : First Quarter 2024 Earnings Presentation
Apellis Pharmaceuticals Q1 Net Loss Narrows, Revenue Rises
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q1 Revenue $172.3M
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2JAAW Aktie
  4. Nachrichten Apellis Pharmaceuticals, Inc.
  5. Andere Sprachen